FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Hillmen

Research Profile

Disorders

Chemicals & Drugs

Procedures

Anatomy

B-Lymphocytes

Concepts & Ideas

Physiology

Mutation

Co-author Network

Publications

TOP 3
Peter Hillmen
Richter's syndrome: CLL taking a turn for the worse.
David Oscier; Andrew Pettitt; Anna Schuh; Jennifer Wimperis; Efrem Eren; Claire Dearden; Efrem Erem; Christopher Fegan; George Follows; Peter Hillmen; Tim Illidge; Estella Matutes; Don W Milligan
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
Anita Hill; Richard Kelly; Gus Khurisgara; Stephen J Richards; Robert J Sapsford; Andrew Scally; Mohan U Sivananthan; Peter Hillmen
Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Hillmen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Peter Hillmen
Richter's syndrome: CLL taking a turn for the worse.
Oncology (Williston Park, N.Y.) 2012;26(12):1155-6.
2012: David Oscier; Andrew Pettitt; Anna Schuh; Jennifer Wimperis; Efrem Eren; Claire Dearden; Efrem Erem; Christopher Fegan; George Follows; Peter Hillmen; Tim Illidge; Estella Matutes; Don W Milligan
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
British journal of haematology 2012;159(5):541-64.
2012: Anita Hill; Richard Kelly; Gus Khurisgara; Stephen J Richards; Robert J Sapsford; Andrew Scally; Mohan U Sivananthan; Peter Hillmen
Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function.
British journal of haematology 2012;158(3):409-14.
2012: Peter Hillmen
Update in paroxysmal nocturnal hemoglobinuria.
Clinical advances in hematology & oncology : H&O 2012;10(6):391-3.
2012: jecko thachil; Tim Webster; Peter Hillmen; Richard Kelly; Vanessa Martlew; Anita Hill
Lessons from an incidental diagnosis of paroxysmal nocturnal haemoglobinuria.
Annals of hematology 2012;91(6):975-6.
2012: Andrew R Pettitt; Stephen Proctor; John A Radford; Andrew Rawstron; Anna Schuh; Richard Jackson; Gillian G Johnson; Anton Kruger; Estella Matutes; Melanie Oates; David Oscier; Samir Agrawal; David J Allsup; Adrian Bloor; Julie Blundell; Stacey Carruthers; Daniel Catovsky; Claire E Dearden; Stephen Devereux; James Dodd; Susanna Dodd; George A Follows; Terry J Hamblin; Earnest Heartin; Peter Hillmen
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(14):1647-55.
2012: Clemens-Martin Wendtner; Jennie Zhang; Adrian Bloor; Francesc Bosch; Andreas Bühler; Steven Coutré; Luke Dreisbach; Alessandra Ferrajoli; Olga Frankfurt; Richard R Furman; Marco Gobbi; John G Gribben; Michael Hallek; Nyla A Heerema; Peter Hillmen; David D Hurd; Eva Kimby; Daruka Mahadevan; Laure Moutouh-de Parseval; Mikkael A Sekeres; Sheetal Shah; Stephan Stilgenbauer; Lutz Uharek; Asher A Chanan-Khan
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Leukemia & lymphoma 2012;53(3):417-23.
2012: Peter Hillmen
Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(5):469-70.
2011: Onima Chowdhury; George A Follows; Peter Hillmen; Jonathon Pattinson; Adrian Bloor; P Carrington; Abraham Varghese; Anna Schuh
Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme.
British journal of haematology 2011;155(4):519-21.
2011: Richard J Kelly; Lindsay D Mitchell; Stephen J Richards; Louise M Arnold; Gemma L Brooksbank; Dena R Cohen; Matthew Cullen; Walter M Gregory; Anita Hill; Peter Hillmen
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.
Blood 2011;117(25):6786-92.
2011: Peter Hillmen; Dena R Cohen; Kim Cocks; Andrew Pettitt; Hazem A Sayala; Andy C Rawstron; Daniel B Kennedy; Christopher Fegan; Don W Milligan; John Radford; Jane Mercieca; Claire Dearden; Raphael Ezekwisili; Alexandra F Smith; Julia Brown; Gillian A Booth; Abraham M Varghese; Christopher Pocock
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
British journal of haematology 2011;152(5):570-8.
2010: Antonio M Risitano; Rosario Notaro; Lucio Luzzatto; Anita Hill; Richard Kelly; Peter Hillmen
Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab.
The New England journal of medicine 2010;363(23):2270-2.
2010: Peter Hillmen
Chronic lymphocytic leukaemia--moving towards cure?
Lancet 2010;376(9747):1122-4.
2010: Peter Hillmen; Modupe Elebute; Richard Kelly; Alvaro Urbano-Ispizua; Anita Hill; Russell P Rother; Gus Khursigara; Chieh-Lin Fu; Mitsuhiro Omine; Paul Browne; Wendell Rosse
Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
American journal of hematology 2010;85(8):553-9.
2010: Anita Hill; Russell P Rother; Xunde Wang; Sidney M Morris; Kerry Quinn-Senger; Richard Kelly; Stephen J Richards; Monica Bessler; Leonard Bell; Peter Hillmen; Mark T Gladwin
Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 2010;149(3):414-25.
2010: Richard Kelly; Louise Arnold; Stephen Richards; Anita Hill; Charlotte Bomken; John Hanley; Andrew Loughney; Jon Beauchamp; Gus Khursigara; Russell P Rother; Elizabeth Chalmers; Andrew Fyfe; Edward Fitzsimons; Ryotaro Nakamura; Anna Gaya; Antonio M Risitano; Jörg Schubert; Derek R Norfolk; Nigel Simpson; Peter Hillmen
The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab.
British journal of haematology 2010;149(3):446-50.
2010: William G Wierda; Thomas J Kipps; Jirí Mayer; Stephan Stilgenbauer; Cathy D Williams; Andrzej Hellmann; Tadeusz Robak; Richard R Furman; Peter Hillmen; Marek Trneny; Martin J S Dyer; Swami Padmanabhan; Magdalena Piotrowska; Tomas Kozak; Geoffrey Chan; Randy Davis; Nedjad Losic; Joris Wilms; Charlotte A Russell; Anders Osterborg
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1749-55.
2010: Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
Haematologica 2010;95(4):567-73.
2010: Andy C Rawstron; Peter Hillmen
Clinical and diagnostic implications of monoclonal B-cell lymphocytosis.
Best practice & research. Clinical haematology 2010;23(1):61-9.
2010: Andy C Rawstron; Jane Shingles; Ruth de Tute; Fiona Bennett; Andrew S Jack; Peter Hillmen
Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing.
Cytometry. Part B, Clinical cytometry 2010;78 Suppl 1():S42-6.
2010: Andy C Rawstron; Tait Shanafelt; Mark C Lanasa; Ola Landgren; Curtis Hanson; Alberto Orfao; Peter Hillmen; Paolo Ghia
Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL).
Cytometry. Part B, Clinical cytometry 2010;78 Suppl 1():S19-23.
2010: Abraham M Varghese; Andy C Rawstron; Peter Hillmen
Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment?
Current hematologic malignancy reports 2010;5(1):35-44.
2009: Michael Kirwan; Tom Vulliamy; Anna Marrone; Amanda J Walne; Richard Beswick; Peter Hillmen; Richard Kelly; Andrew Stewart; David Bowen; Stefan O Schonland; Annika Maria Whittle; Anthony McVerry; Maria Gilleece; Inderjeet Dokal
Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia.
Human mutation 2009;30(11):1567-73.
2009: Richard Kelly; Stephen Richards; Peter Hillmen; Anita Hill
The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.
Therapeutics and clinical risk management 2009;5():911-21.
2009: Neal S Young; Gabrielle Meyers; Hubert Schrezenmeier; Peter Hillmen; Anita Hill
The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients.
Seminars in hematology 2009;46(1 Suppl 1):S1-S16.
2009: Claes Karlsson; Jeanette Lundin; Eva Kimby; Ben Kennedy; Paul Moreton; Peter Hillmen; Anders Osterborg
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
British journal of haematology 2009;144(1):78-85.
2009: Stephen J Richards; Liam Whitby; Matthew J Cullen; Anita J Dickinson; Viv Granger; Peter Hillmen; John T Reilly; David Barnett
Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry.
Cytometry. Part B, Clinical cytometry 2009;76(1):47-55.
2008: Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; richard Houlston
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.
Nature genetics 2008;40(10):1204-10.
2008: Andy C Rawstron; Fiona L Bennett; Sheila J M O'Connor; Marwan Kwok; James A L Fenton; Marieth Plummer; Ruth de Tute; Roger G Owen; Stephen J Richards; Andrew S Jack; Peter Hillmen
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
The New England journal of medicine 2008;359(6):575-83.
2008: Abraham M Varghese; Hazem Sayala; Paul A S Evans; Sheila J M O'Connor; Russell Patmore; Peter Hillmen; Roger G Owen
Development of EBV-associated diffuse large B-cell lymphoma in Waldenstrom macroglobulinemia and mantle cell lymphoma.
Leukemia & lymphoma 2008;49(8):1618-9.
2008: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti Rai; Thomas Kipps
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.
Blood 2008;111(12):5446-56.
2008: Jörg Schubert; Peter Hillmen; Alexander Röth; Neal S Young; Modupe Elebute; Jeff Szer; Giacomo Gianfaldoni; Gérard Socié; Paul Browne; Robert Geller; Russell P Rother; Petra Muus
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 2008;142(2):263-72.
2008: Robert A Brodsky; Neal S Young; Elisabetta Antonioli; Antonio M Risitano; Hubert Schrezenmeier; Jörg Schubert; Anna Gaya; Luke Coyle; Carlos de Castro; Chieh-Lin Fu; Jaroslaw P Maciejewski; Monica Bessler; Henk-André Kroon; Russell P Rother; Peter Hillmen
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.
Blood 2008;111(4):1840-7.
2008: Andy C Rawstron; Peter Hillmen
Assessing minimal residual disease in chronic lymphocytic leukemia.
Current hematologic malignancy reports 2008;3(1):47-53.
2008: Peter Hillmen
The role of complement inhibition in PNH.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008;():116-23.
2008: Richard L Haspel; Peter Hillmen
Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence-based review 2008.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008;():35.
2007: Peter Hillmen; Aleksander B Skotnicki; Tadeusz Robak; Branimir Jaksic; Anna Dmoszynska; Jingyang Wu; Cynthia Sirard; Jiri Mayer
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(35):5616-23.
2007: Andy C Rawstron; Fiona Bennett; Peter Hillmen
The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia.
British journal of haematology 2007;139(5):724-9.
2007: Andy C Rawstron; Richard A Jones; Carol Ferguson; Geraint Hughes; Pam Selby; Carol Reid; Surita Dalal; Martin Howard; Graeme Smith; Peter Hillmen; Roger G Owen; Andrew S Jack
Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience.
British journal of haematology 2007;139(5):845-8.
2007: Peter Hillmen; Petra Muus; Ulrich Dührsen; Antonio M Risitano; Jörg Schubert; Lucio Luzzatto; Hubert Schrezenmeier; Jeff Szer; Robert A Brodsky; Anita Hill; Gérard Socié; Monica Bessler; Scott A Rollins; Leonard Bell; Russell P Rother; Neal S Young
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Blood 2007;110(12):4123-8.
2007: Fiona Bennett; Andy C Rawstron; Marieth Plummer; Ruth de Tute; Paul Moreton; Andrew Jack; Peter Hillmen
B-cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle.
British journal of haematology 2007;139(4):600-4.
2007: Hazem A Sayala; Andy C Rawstron; Peter Hillmen
Minimal residual disease assessment in chronic lymphocytic leukaemia.
Best practice & research. Clinical haematology 2007;20(3):499-512.
2007: Stephen J Richards; Anita Hill; Peter Hillmen
Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.
Cytometry. Part B, Clinical cytometry 2007;72(5):291-8.
2007: D R Mould; A Baumann; J Kuhlmann; M J Keating; Steven D Weitman; Peter Hillmen; Lee R Brettman; S Reif; Peter L Bonate
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.
British journal of clinical pharmacology 2007;64(3):278-91.
2007: Daniel Catovsky; S Richards; Estella Matutes; David Oscier; Martin J S Dyer; R F Bezares; Andrew R Pettitt; Terry J Hamblin; D W Milligan; J A Child; malcolm Hamilton; Claire Dearden; A G Smith; A G Bosanquet; Zadie Davis; Vasantha Brito-Babapulle; M Else; R Wade; Peter Hillmen
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Lancet 2007;370(9583):230-9.
2007: Anita Hill; Stephen J Richards; Peter Hillmen
Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.
British journal of haematology 2007;137(3):181-92.
2007: Andy C Rawstron; N Villamor; Matthias Ritgen; Sebastian Böttcher; Paolo Ghia; J L Zehnder; G Lozanski; D Colomer; C Moreno; Massimo Geuna; P A S Evans; Yasodha Natkunam; S E Coutre; E D Avery; Laura Rassenti; Thomas Kipps; Federico Caligaris-Cappio; Michael Kneba; J C Byrd; Michael Hallek; E Montserrat; Peter Hillmen
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Leukemia 2007;21(5):956-64.
2007: Anita Hill; Stephen J Richards; Russell P Rother; Peter Hillmen
Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
Haematologica 2007;92(3):e31-3.
2007: Chadi Nabhan; Steven Coutré; Peter Hillmen
Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?
British journal of haematology 2007;136(3):379-92.
2006: Andy C Rawstron; Ruth de Tute; Andrew S Jack; Peter Hillmen
Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens.
Leukemia 2006;20(12):2102-10.
2006: Andy C Rawstron; Giles Laycock-Brown; Geoff Hale; Faith E Davies; Gareth J Morgan; J Anthony Child; Peter Hillmen; Roger G Owen
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
Haematologica 2006;91(11):1577-8.
2006: Peter Hillmen; Neal S Young; Jörg Schubert; Robert A Brodsky; Gérard Socié; Petra Muus; Alexander Röth; Jeff Szer; Modupe Elebute; Ryotaro Nakamura; Paul Browne; Antonio M Risitano; Anita Hill; Hubert Schrezenmeier; Chieh-Lin Fu; Jaroslaw Maciejewski; Scott A Rollins; Christopher F Mojcik; Russell P Rother; Lucio Luzzatto
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
The New England journal of medicine 2006;355(12):1233-43.
2006: Antonio M Almeida; Yoshiko Murakami; D Mark Layton; Peter Hillmen; Gabrielle Sellick; Yusuke Maeda; Stephen Richards; Scott Patterson; Ioannis Kotsianidis; Luigina R Mollica; Dorothy H Crawford; Alastair Baker; Michael Ferguson; Irene Roberts; Richard Houlston; Taroh Kinoshita; Anastasios Karadimitris
Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency.
Nature medicine 2006;12(7):846-51.
2006: Peter Hillmen
MRD in CLL.
Clinical advances in hematology & oncology : H&O 2006;4(5):6-7; discussion 10; suppl 12.
2006: Peter Hillmen
Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
Seminars in oncology 2006;33(2 Suppl 5):S23-8.
2006: Ruth de Tute; Martin Yuille; D Catovsky; R S Houlston; Peter Hillmen; Andy C Rawstron
Monoclonal B-cell lymphocytosis (MBL) in CLL families: substantial increase in relative risk for young adults.
Leukemia 2006;20(4):728-9.
2006: Anita Hill; Simon H Ridley; Dirk Esser; Rodney G Oldroyd; Matthew J Cullen; Paula Kareclas; Seán Gallagher; Geoffrey P Smith; Stephen J Richards; Jennifer White; Richard A G Smith; Peter Hillmen
Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy.
Blood 2006;107(5):2131-7.
2006: Jacques-Louis Binet; Federico Caligaris-Cappio; Daniel Catovsky; Bruce D Cheson; Tom Davis; Guillaume Dighiero; Hartmut Döhner; Michael Hallek; Peter Hillmen; Michael Keating; Emili Montserrat; Thomas Kipps; Kanti Rai
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia.
Blood 2006;107(3):859-61.
2005: Anita Hill; Russell P Rother; Peter Hillmen
Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
Haematologica 2005;90(12 Suppl):ECR40.
2005: Stefan Faderl; Steven Coutré; John C Byrd; Claire Dearden; A Denes; Martin J S Dyer; S A Gregory; J G Gribben; Peter Hillmen; Michael Keating; S Rosen; P Venugopal; Kanti Rai
The evolving role of alemtuzumab in management of patients with CLL.
Leukemia 2005;19(12):2147-52.
2005: Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell F Rosse; Gérard Socié
Diagnosis and management of paroxysmal nocturnal hemoglobinuria.
Blood 2005;106(12):3699-709.
2005: Peter Hillmen
Chronic lymphocytic leukemia--aiming at a moving target!
Haematologica 2005;90(11):1451-2.
2005: Anita Hill; Peter Hillmen; Stephen J Richards; Modupe Elebute; Judith C W Marsh; Jason Chan; Christopher F Mojcik; Russell P Rother
Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria.
Blood 2005;106(7):2559-65.
2005: Gerald E Marti; Andy C Rawstron; Paolo Ghia; Peter Hillmen; richard Houlston; Neil Kay; Thérèse A Schleinitz; Neil Caporaso
Diagnostic criteria for monoclonal B-cell lymphocytosis.
British journal of haematology 2005;130(3):325-32.
2005: Peter Hillmen
Minimal residual disease and survival in chronic lymphocytic leukemia.
Clinical advances in hematology & oncology : H&O 2005;3(7):522-4.
2005: Paul Moreton; Ben Kennedy; Guy Lucas; Michael Leach; Saad M B Rassam; Andrew Haynes; Jane Tighe; David Oscier; Christopher Fegan; Andy C Rawstron; Peter Hillmen
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2971-9.
2005: Russell P Rother; Leonard Bell; Peter Hillmen; Mark T Gladwin
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease.
JAMA : the journal of the American Medical Association 2005;293(13):1653-62.
2005: D Wayne Thomas; Roger G Owen; Stephen A N Johnson; Peter Hillmen; John F Seymour; Max M Wolf; Simon A J Rule
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
Leukemia & lymphoma 2005;46(4):549-52.
2005: Roger G Owen; Peter Hillmen; Andy C Rawstron
CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.
Clinical lymphoma 2005;5(4):278-81.
2004: Geoff Hale; Peppy Rebello; Lee R Brettman; Christopher Fegan; Ben Kennedy; Eva Kimby; Mike Leach; Jeanette Lundin; Håkan Mellstedt; Paul Moreton; Andy C Rawstron; Herman Waldmann; Anders Osterborg; Peter Hillmen
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Blood 2004;104(4):948-55.
2004: Andy C Rawstron; Peter Hillmen; Richard Houlston
Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients.
Seminars in hematology 2004;41(3):192-200.
2004: David Oscier; Christopher Fegan; Peter Hillmen; T Illidge; S Johnson; P Maguire; Estella Matutes; Donald Milligan
Guidelines on the diagnosis and management of chronic lymphocytic leukaemia.
British journal of haematology 2004;125(3):294-317.
2004: Andy C Rawstron; Ben Kennedy; Paul Moreton; Anita J Dickinson; Matthew J Cullen; Stephen J Richards; Andrew S Jack; Peter Hillmen
Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.
Blood 2004;103(6):2027-31.
2004: Michael Keating; Steven Coutré; Kanti Rai; Anders Osterborg; Stefan Faderl; Ben Kennedy; Tom Kipps; Gerald P Bodey; John C Byrd; Steven Rosen; Claire Dearden; Martin J S Dyer; Peter Hillmen
Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia.
Clinical lymphoma 2004;4(4):220-7.
2004: Peter Hillmen; Claire Hall; Judith C W Marsh; Modupe Elebute; Michael P Bombara; Beth E Petro; Matthew J Cullen; Stephen J Richards; Scott A Rollins; Christopher F Mojcik; Russell P Rother
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
The New England journal of medicine 2004;350(6):552-9.
2004: Peter Hillmen
Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Seminars in oncology 2004;31(1 Suppl 2):22-6.
2004: Wendell F Rosse; Peter Hillmen; Alan D Schreiber
Immune-mediated hemolytic anemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2004;():48-62.
2004: Peter Hillmen
Future prospects for fludarabine-containing regimens in the treatment of hematological cancers.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5 Suppl 1():S76-86.
2003: Claire Hall; Stephen Richards; Peter Hillmen
Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH).
Blood 2003;102(10):3587-91.
2003: Paul Moreton; Peter Hillmen
Alemtuzumab therapy in B-cell lymphoproliferative disorders.
Seminars in oncology 2003;30(4):493-501.
2002: Andy C Rawstron; Martin Yuille; Julie Fuller; Matthew Cullen; Ben Kennedy; Stephen J Richards; Andrew S Jack; Estella Matutes; Daniel Catovsky; Peter Hillmen; richard Houlston
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.
Blood 2002;100(7):2289-90.
2002: Andy C Rawstron; Michael J Green; Anita Kuzmicki; Ben Kennedy; James A L Fenton; Paul A S Evans; Sheila J M O'Connor; Stephen J Richards; Gareth J Morgan; Andrew S Jack; Peter Hillmen
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.
Blood 2002;100(2):635-9.
2002: R J Johnson; Peter Hillmen
Paroxysmal nocturnal haemoglobinuria: nature's gene therapy?
Molecular pathology : MP 2002;55(3):145-52.
2002: Michael J Keating; Ian W Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee R Brettman; Pedro Santabarbara; Bret Wacker; Kanti Rai
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Blood 2002;99(10):3554-61.
2002: Stephen J Richards; Peter Hillmen
Immunophenotypic analysis of PNH cells.
Current protocols in cytometry / editorial board, J. Paul Robinson, managing editor ... [et al.] 2002;Chapter 6():Unit 6.11.
2002: Ben Kennedy; Andy C Rawstron; Chris Carter; Mary Ryan; Kevin Speed; Guy Lucas; Peter Hillmen
Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.
Blood 2002;99(6):2245-7.
2002: Claire Hall; Stephen J Richards; Peter Hillmen
The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria/aplasia model.
Acta haematologica 2002;108(4):219-30.
2002: Ben Kennedy; Peter Hillmen
Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.
Medical oncology (Northwood, London, England) 2002;19 Suppl():S49-55.
2001: Andy C Rawstron; Ben Kennedy; Paul A S Evans; Faith E Davies; Stephen J Richards; Andrew P Haynes; N H Russell; Geoff Hale; Gareth J Morgan; Andrew S Jack; Peter Hillmen
Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.
Blood 2001;98(1):29-35.
2000: Stephen J Richards; Gareth J Morgan; Peter Hillmen
Immunophenotypic analysis of B cells in PNH: insights into the generation of circulating naive and memory B cells.
Blood 2000;96(10):3522-8.
2000: Stephen J Richards; Andy C Rawstron; Peter Hillmen
Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria.
Cytometry 2000;42(4):223-33.
2000: Peter Hillmen; Stephen J Richards
Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria.
British journal of haematology 2000;108(3):470-9.
1999: Stephen J Richards; Gareth J Morgan; Peter Hillmen
Analysis of T cells in paroxysmal nocturnal hemoglobinuria provides direct evidence that thymic T-cell production declines with age.
Blood 1999;94(8):2790-9.
1999: Andy C Rawstron; Sara Rollinson; S Richards; M A Short; Anne English; Gareth J Morgan; G Hale; Peter Hillmen
The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.
British journal of haematology 1999;107(1):148-53.
1998: Stephen J Richards; Derek R Norfolk; David M Swirsky; Peter Hillmen
Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria.
Blood 1998;92(5):1799-806.
1998: Monica Bessler; Peter Hillmen
Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria.
Seminars in hematology 1998;35(2):149-67.
1997: Sara Rollinson; S Richards; Derek R Norfolk; K Bibi; G Morgan; Peter Hillmen
Both paroxysmal nocturnal hemoglobinuria (PNH) type II cells and PNH type III cells can arise from different point mutations involving the same codon of the PIG-A gene.
Blood 1997;89(8):3069-71.
1996: Khedoudja Nafa; Monica Bessler; P Mason; T Vulliamy; Peter Hillmen; Hugo Castro-Malaspina; Lucio Luzzatto
Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis.
Haematologica 1996;81(6):540-2.
1996: Mary Frances McMullin; Peter Hillmen; G E Elder; Terence R J Lappin; Lucio Luzzatto
Serum erythropoietin levels in paroxysmal nocturnal haemoglobinuria: implications for therapy.
British journal of haematology 1996;92(4):815-7.
1995: Khedoudja Nafa; Philip J Mason; Peter Hillmen; Lucio Luzzatto; Monica Bessler
Mutations in the PIG-A gene causing paroxysmal nocturnal hemoglobinuria are mainly of the frameshift type.
Blood 1995;86(12):4650-5.
1995: Peter Hillmen; S M Lewis; Monica Bessler; Lucio Luzzatto; J V Dacie
Natural history of paroxysmal nocturnal hemoglobinuria.
The New England journal of medicine 1995;333(19):1253-8.
1994: R P Rother; S A Rollins; J Mennone; A Chodera; S A Fidel; Monica Bessler; Peter Hillmen; S P Squinto
Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement.
Blood 1994;84(8):2604-11.
1994: Monica Bessler; Philip J Mason; Peter Hillmen; Lucio Luzzatto
Mutations in the PIG-A gene causing partial deficiency of GPI-linked surface proteins (PNH II) in patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 1994;87(4):863-6.
1994: Monica Bessler; Peter Hillmen; L Longo; Lucio Luzzatto; Philip J Mason
Genomic organization of the X-linked gene (PIG-A) that is mutated in paroxysmal nocturnal haemoglobinuria and of a related autosomal pseudogene mapped to 12q21.
Human molecular genetics 1994;3(5):751-7.
1994: Monica Bessler; P Mason; Peter Hillmen; Lucio Luzzatto
Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria.
Lancet 1994;343(8903):951-3.
1994: Monica Bessler; Philip J Mason; Peter Hillmen; T Miyata; N Yamada; J Takeda; Lucio Luzzatto; T Kinoshita
Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene.
The EMBO journal 1994;13(1):110-7.
1994: Mary Frances McMullin; Peter Hillmen; J Jackson; P Ganly; Lucio Luzzatto
Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria.
Journal of internal medicine 1994;235(1):85-9.
1993: Peter Hillmen; Monica Bessler; Philip J Mason; W M Watkins; Lucio Luzzatto
Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(11):5272-6.
1993: Peter Hillmen; Monica Bessler; J Bungey; Lucio Luzzatto
Paroxysmal nocturnal hemoglobinuria: correction of abnormal phenotype by somatic cell hybridization.
Somatic cell and molecular genetics 1993;19(2):123-9.
1993: Peter Hillmen; Monica Bessler; D H Crawford; Lucio Luzzatto
Production and characterization of lymphoblastoid cell lines with the paroxysmal nocturnal hemoglobinuria phenotype.
Blood 1993;81(1):193-9.
1992: Monica Bessler; Peter Hillmen; Lucio Luzzatto
Clonal origin of abnormal granulocytes in paroxysmal nocturnal hemoglobinuria.
Blood 1992;80(3):844-5.
1992: Peter Hillmen; Jill M Hows; Lucio Luzzatto
Two distinct patterns of glycosylphosphatidylinositol (GPI) linked protein deficiency in the red cells of patients with paroxysmal nocturnal haemoglobinuria.
British journal of haematology 1992;80(3):399-405.
1991: J Beard; Peter Hillmen; C C Anderson; S M Lewis; Thomas C Pearson
Primary thrombocythaemia in pregnancy.
British journal of haematology 1991;77(3):371-4.